Outset Medical (NASDAQ:OM) Announces Earnings Results, Misses Expectations By $0.04 EPS

Outset Medical (NASDAQ:OM) posted its quarterly earnings results on Wednesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04), Zacks reports. The company had revenue of $29.47 million during the quarter, compared to analysts’ expectations of $28.47 million. Outset Medical had a negative return on equity of 175.64% and a negative net margin of 112.57%. Outset Medical updated its FY 2025 guidance to EPS.

Outset Medical Price Performance

Shares of NASDAQ OM traded down $0.06 during trading on Friday, hitting $0.90. The company had a trading volume of 221,380 shares, compared to its average volume of 1,416,528. The stock has a fifty day simple moving average of $0.95 and a two-hundred day simple moving average of $0.85. Outset Medical has a fifty-two week low of $0.44 and a fifty-two week high of $5.22. The firm has a market capitalization of $48.54 million, a price-to-earnings ratio of -0.36 and a beta of 2.01. The company has a quick ratio of 5.04, a current ratio of 6.49 and a debt-to-equity ratio of 4.12.

Insider Activity

In other Outset Medical news, CEO Leslie Trigg sold 33,227 shares of Outset Medical stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $0.81, for a total transaction of $26,913.87. Following the transaction, the chief executive officer now directly owns 861,397 shares of the company’s stock, valued at $697,731.57. The trade was a 3.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel John L. Brottem sold 32,930 shares of Outset Medical stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $0.80, for a total transaction of $26,344.00. Following the transaction, the general counsel now directly owns 181,188 shares in the company, valued at $144,950.40. This trade represents a 15.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 292,750 shares of company stock worth $244,707 over the last 90 days. 4.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, Royal Bank of Canada restated a “sector perform” rating and set a $3.00 price target on shares of Outset Medical in a research report on Tuesday, January 7th.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.